Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.

中文翻译：

---

非小细胞肺癌中PBRM1突变和免疫检查点阻断治疗的初步反应

Polybromo -1（PBRM1）基因是一种在透明细胞肾细胞癌中用于免疫治疗的有前途的生物标志物。但是据我们所知，肺癌中PBRM1突变的频率和临床相关性仍然未知。我们进行了一项回顾性研究，以评估PBRM1突变的发生率及其与非小细胞肺癌（NSCLC）对免疫治疗的初步反应的相关性。我们的结果表明，PBRM1突变更可能是NSCLC免疫治疗的阴性预测生物标志物。